{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:28Z","timestamp":1791404368443,"version":"4.3.3"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Selinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant incorporation into widespread practice. Here, our objective is to provide updated clinical evidence highlighting the preserved efficacy and improved tolerability of once-weekly selinexor at lower doses in patients with previously treated MM compared to twice-weekly regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient-level data from the BOSTON, STOMP, STORM, and XPORT-MM-028 clinical trials were systematically evaluated to elucidate relationships between selinexor dosing schedule, regimen toxicities, and efficacy in patients with MM that had progressed after at least one prior therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Updated results on once-weekly selinexor in combination with other anti-MM agents showed a reduced adverse event profile and improved tolerability compared with twice-weekly selinexor regimens, without compromise in efficacy. Furthermore, new data from several regimens with weekly selinexor delivery suggest that patients who had selinexor dose reductions or were treated in cohorts with a lower selinexor starting dose had reduced rates of adverse events, and superior durations of response. Weekly selinexor in combination with pomalidomide or carfilzomib in particular showed efficacy in difficult-to-treat, multiclass relapsed\/refractory MM, including MM refractory to prior BCMA-directed therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a rapidly evolving field of previously treated MM, lowering of selinexor dose and frequency into weekly regimens showed a more feasible and tolerable treatment with continued efficacy when compared to twice-weekly schedules, paving the path for effective management of multiclass refractory MM, including patients with very advanced disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1649493","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:12:41Z","timestamp":1758514361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy"],"prefix":"10.3389","volume":"15","author":[{"given":"Muhamed","family":"Baljevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane R.","family":"Van Domelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000504","article-title":"Thalidomide and its derivatives: new promise for multiple myeloma","volume":"10","author":"Weber","year":"2003","journal-title":"Cancer Control"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/J.SEMINHEMATOL.2005.10.004","article-title":"Management of the relapsed\/refractory myeloma patient: strategies incorporating lenalidomide","volume":"42","author":"Richardson","year":"2005","journal-title":"Semin Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/BLOOD-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/BLOOD-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"New Engl J Med"},{"key":"B10","unstructured":"XPOVIO\u00ae (selinexor), package insert\n          \n          \n          \n          2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomized, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124370","article-title":"Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in patients with newly diagnosed multiple myeloma","volume":"134","author":"White","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2020-140141","article-title":"Selinexor, lenalidomide and dexamethasone (SRd) for patients with relapsed\/refractory and newly diagnosed multiple myeloma","volume":"136","author":"White","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/JHA2.122","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto","year":"2021","journal-title":"EJHaem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1352281","article-title":"Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"14","author":"White","year":"2024","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.clml.2023.08.018","article-title":"Association of selinexor dose reductions with clinical outcomes in the BOSTON study","volume":"23","author":"Jagannath","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomized, multicenter, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomized, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/S41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/J.CLML.2023.06.001","article-title":"Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies","volume":"23","author":"Schiller","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/JHA2.572","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment","volume":"3","author":"Baljevic","year":"2022","journal-title":"EJHaem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results","volume":"39","author":"Anderson Larry","year":"2021","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2021-146060","article-title":"Updated results from CARTITUDE-1: phase 1b\/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/BLOOD-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMOA2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_SUPPL.8006","article-title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_SUPPL.8015","article-title":"Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1","volume":"40","author":"Minnema","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B32","article-title":"Initial clinical activity and safety of BFCR4350A, a fcRH5\/CD3 T-cell-engaging bispecific antibody","volume-title":"Relapsed\/Refractory Multiple Myeloma, Blood","author":"Cohen","year":"2020"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-139192","volume-title":"REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM), Blood","author":"Madduri","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-168610","article-title":"Phase II Study of fully human BCMA-targeting CAR-T cells (Zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-163827","article-title":"Phase 1 study of CART-ddbcma for the treatment of subjects with relapsed and\/or refractory multiple myeloma","volume":"140","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146210","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: A randomized, phas","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLMED.2024.05.001","article-title":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","volume":"30","author":"Colley","year":"2024","journal-title":"Trends Mol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/S2152-2650(24)02310-3","article-title":"P-408 survival analysis of selinexor-exposed relapsed\/refractory multiple myeloma (RRMM) treated with chimeric antigen receptor T-cell (CAR-T) therapy: A real-world exploratory analysis","volume":"24","author":"Dima","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16550","article-title":"Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy","volume":"189","author":"Chari","year":"2020","journal-title":"Br J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31010034","article-title":"Impact of a best practices program in patients with relapsed\/refractory multiple myeloma receiving selinexor","volume":"31","author":"Gordan","year":"2024","journal-title":"Curr Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:12:43Z","timestamp":1758514363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":45,"alternative-id":["10.3389\/fonc.2025.1649493"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1649493","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1649493"}}